GenAide is turning India’s pharma chaos into a predictable export engine

India exports nearly $27 billion worth of pharmaceutical products every year. Yet the country’s manufacturing backbone tells a different story: thousands of certified plants, many compliant with WHO, EU GMP and export-grade norms, run at barely 60% capacity. 

Their struggle is not production. It is everything after production, such as scattered documentation, unpredictable logistics, volatile pricing, slow responses from international buyers, and the absence of a dependable execution layer.

“What we kept seeing was the same paradox. On paper, India has world-class formulation and API (Active Pharmaceutical Ingredient) capability. But the moment the product leaves the factory gate, everything becomes uncertain, timelines, documents, even basic communication. The factories could make the drug. The real struggle was getting it reliably to another continent,” Sagar Khetiya, Co-founder, GenAide, tells YourStory. 

What GenAide does

Based in Ahmedabad, GenAide Pharma works as an exporter on record for Indian pharmaceutical SMEs. Instead of simply connecting buyers and manufacturers, the startup purchases from Indian facilities and manages the entire export journey, including regulatory documentation, dossier preparation, facility audits, packaging compliance, freight negotiations, customs, insurance, invoicing, and credit cycles.

“Most SMEs don’t struggle with quality. They struggle with the maze of paperwork, unpredictable audits, shifting global norms, and the sheer burden of compliance. We stepped in as the exporter on record because the only way to fix the system was to own accountability end-to-end, pricing, documentation, logistics, everything,” he explains.

Over the years, GenAide has built one of the largest structured catalogues in the SME segment, 5,000 products (nearly 4,000 APIs and 1,000 formulations) sourced from a vetted pool of 800+ manufacturers across India.

“The Indian ecosystem is rich, but it’s also deeply fragmented. A single product could have five versions of documentation, three formats of stability data and no unified audit trail. It took us seven years to map, verify, audit, and standardise 800 manufacturers before adding them to our catalogue. Quality is useless unless it’s documented, structured and export-ready,” Khetiya notes.

The startup now supports registrations across multiple continents, listing over 60 approved products, over 100 under submission, and 120 more in the pipeline. It operates in over 10 international markets, serves more than 40 customers, and has handled over 1,000 export shipments.

“For an SME manufacturer, one product registration abroad can take 12–24 months. We compress that because we already know what each regulator expects, the gaps, the red flags, the formats. Our mission is simple: make Indian pharma easy, predictable and trustworthy to buy from, anywhere in the world,” he says.

How the journey began

GenAide was incorporated in 2016 as GenAide Pharmaceutical LLP. In its early years, the firm was a side operation run by Jigar Chaudhary and Navin Chaudhari, who took on occasional export requests while maintaining full-time careers. The shift to a full-time business happened only in 2022, when Yash Khetiya, Deep Vanecha, and Sagar Khetiya joined the venture.

In March 2024, the startup transitioned into a Private Limited structure as volumes, documentation work, and regulatory responsibilities expanded. 

Global competition made things harder. Chinese suppliers often responded faster and provided more flexible credit terms. Indian SMEs were not losing out due to quality, they were losing because their systems weren’t predictable.

Building predictability in a 47-step export chain

The export of a single pharma product passes through 47 operational checkpoints involving domestic carriers, handlers, freight agents, insurers, customs authorities, and destination-country regulators. Even a two-hour disruption can force a full documentation reset.

To counter this, GenAide built an internal workflow engine that tracks every movement with e-commerce-style updates, and added redundancy via failover networks across transporters and handlers.

“Aggregation may not sound glamorous. But it gives you redundancy. And redundancy is the only thing that guarantees timelines in Indian logistics. We learned early that reliability is built, not hoped for,” Khetiya says.

Quality risks are controlled through a double-testing protocol, first at the manufacturer, then through an independent lab. Credit risks are narrowed through conservative limits, staged extensions, and ECGC-backed insurance covering more than $1 million. 

The cashflow friction, one of the biggest SME pain points, is removed by paying manufacturers at dispatch while handling 30–90 day buyer cycles internally.

“Cash flow kills more deals than regulation ever does. When we fixed that, the scale at which SMEs could participate changed overnight. Suddenly, a small unit could supply to four countries instead of one,” Khetiya adds.

Documentation, data, and the trust barrier

Convincing manufacturers to share technical dossiers was the first real roadblock. “In the beginning, nobody wanted to give us their entire product catalogue. For them, these documents are intellectual property. It was like asking a restaurant in 2010 to hand over its full menu to a food app. We had to earn that trust one visit at a time,” he says.

After months of field visits and patient relationship-building, GenAide digitised and standardised thousands of documents, including CoAs, GMP certificates, stability data, and regulatory dossiers, creating a structured library that now powers sourcing, registration, and compliance.

Also Read

Glam and green: How this Shilpa Shetty-backed startup is making sustainable diamonds desirable

“That’s when the opportunity became visible. Every cleaned document unlocked a market we could confidently go after. The data gave us leverage,” Khetiya adds.

Technology as the invisible layer

The startup has built a technology layer that automates sourcing intelligence, buyer communication, regulatory workflows, and registration tracking. Import-pattern analysis helps match buyer requirements with its mapped network of over 800 manufacturing units.

The AI-led upgrades are underway, dossier preparation time has reduced from 45 days to 30, repetitive compliance checks are increasingly automated, and a packaging/label generator developed with Nanobanana speeds up private-label launches.

“AI isn’t here to replace expertise. It’s here to eliminate the parts of the process that slow experts down, the repetitive checks, the manual formatting, the compliance loops. Technology lets us scale quality without scaling chaos,” he says.

The years ahead

GenAide grew from roughly $100,000 in early revenue to $1 million in FY22–23, and $2.2 million in FY23–24, working with 71 suppliers. In 2024, it crossed $2 million by December, and expects the strong January–March cycle to push its annualised run-rate to $4–5 million.

The supplier partnerships are projected to rise to 86 next year.

The startup has raised Rs 2.9 crore in convertible notes from family offices, angels, and an AIF. Over the next five years, it aims to integrate over 250 manufacturers and build a $100 million export engine.

“We’re not trying to be a marketplace. Marketplaces introduce you, they don’t stay with you when things go wrong. We’re building the execution layer for Indian manufacturing. Once exports become predictable, scale is inevitable. That’s the future we’re engineering,” Khetiya says.

GenAide operates alongside B2B pharma export platforms such as IndiaPharma.com, Connect2India, and Venus Marketing. What sets it apart is full accountability for execution.

“We don’t just connect buyers and manufacturers. We own the entire export process, from pricing and documentation to logistics and compliance, so that SMEs can scale reliably without worrying about the messy parts of exports,” he notes.